Real-World Application of a Quantitative Systems Pharmacology (QSP) Model to Predict Potassium Concentrations from Electronic Health Records: A Pilot Case towards Prescribing Monitoring of Spironolactone

被引:0
作者
Meid, Andreas D. [1 ]
Scherkl, Camilo [1 ]
Metzner, Michael [1 ]
Czock, David [1 ]
Seidling, Hanna M. [1 ,2 ]
机构
[1] Heidelberg Univ, Heidelberg Univ Hosp, Med Fac Heidelberg, Internal Med 9,Dept Clin Pharmacol & Pharmacoepide, Neuenheimer Feld 410, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Heidelberg Univ Hosp, Med Fac Heidelberg, Internal Med 9,Dept Clin Pharmacol & Pharmacoepide, Neuenheimer Feld 410, D-69120 Heidelberg, Germany
关键词
potassium; kidney; spironolactone; quantitative systems pharmacology (QSP); electronic health records (EHR); sensitivity analysis; maximum a posteriori (MAP) (Bayesian) estimation; GLOBAL SENSITIVITY-ANALYSIS;
D O I
10.3390/ph17081041
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Quantitative systems pharmacology (QSP) models are rarely applied prospectively for decision-making in clinical practice. We therefore aimed to operationalize a QSP model for potas-sium homeostasis to predict potassium trajectories based on spironolactone administrations. For this purpose, we proposed a general workflow that was applied to electronic health records (EHR) from patients treated in a German tertiary care hospital. The workflow steps included model exploration, local and global sensitivity analyses (SA), identifiability analysis (IA) of model parameters, and specification of their inter-individual variability (IIV). Patient covariates, selected parameters, and IIV then defined prior information for the Bayesian a posteriori prediction of individual potassium trajectories of the following day. Following these steps, the successfully operationalized QSP model was interactively explored via a Shiny app. SA and IA yielded five influential and estimable parameters (extracellular fluid volume, hyperaldosteronism, mineral corticoid receptor abundance, potassium intake, sodium intake) for Bayesian prediction. The operationalized model was validated in nine pilot patients and showed satisfactory performance based on the (absolute) average fold error. This provides proof-of-principle for a Prescribing Monitoring of potassium concentrations in a hospital system, which could suggest preemptive clinical measures and therefore potentially avoid dangerous hyperkalemia or hypokalemia.
引用
收藏
页数:25
相关论文
共 42 条
  • [1] Negligible impact of highly patient-specific decision support for potassium-increasing drug-drug interactions - a cluster-randomised controlled trial
    Beeler, Patrick E.
    Eschmann, Emmanuel
    Schneemann, Markus
    Blaser, Jurg
    [J]. SWISS MEDICAL WEEKLY, 2019, 149
  • [2] Event Analysis for Automated Estimation of Absent and Persistent Medication Alerts: Novel Methodology
    Bittmann, Janina A.
    Scherkl, Camilo
    Meid, Andreas D.
    Haefeli, Walter E.
    Seidling, Hanna M.
    [J]. JMIR MEDICAL INFORMATICS, 2024, 12
  • [3] Evaluation framework for systems models
    Braakman, Sietse
    Pathmanathan, Pras
    Moore, Helen
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (03): : 264 - 289
  • [4] Practical identifiability analysis of large environmental simulation models
    Brun, R
    Reichert, P
    Künsch, HR
    [J]. WATER RESOURCES RESEARCH, 2001, 37 (04) : 1015 - 1030
  • [5] The new biology of aldosterone
    Connell, JMC
    Davies, E
    [J]. JOURNAL OF ENDOCRINOLOGY, 2005, 186 (01) : 1 - 20
  • [6] An industry perspective on current QSP trends in drug development
    Cucurull-Sanchez, Lourdes
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2024, 51 (05) : 511 - 520
  • [7] Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network
    Cucurull-Sanchez, Lourdes
    Chappell, Michael J.
    Chelliah, Vijayalakshmi
    Cheung, S. Y. Amy
    Derks, Gianne
    Penney, Mark
    Phipps, Alex
    Malik-Sheriff, Rahuman S.
    Timmis, Jon
    Tindall, Marcus J.
    van der Graaf, Piet H.
    Vicini, Paolo
    Yates, James W. T.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (05): : 259 - 272
  • [8] State of the Art: Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design
    Dagenais, Simon
    Russo, Leo
    Madsen, Ann
    Webster, Jen
    Becnel, Lauren
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (01) : 77 - 89
  • [9] Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy
    Darwich, Adam S.
    Polasek, Thomas M.
    Aronson, Jeffrey K.
    Ogungbenro, Kayode
    Wright, Daniel F. B.
    Achour, Brahim
    Reny, Jean-Luc
    Daali, Youssef
    Eiermann, Birgit
    Cook, Jack
    Lesko, Lawrence
    McLachlan, Andrew J.
    Rostami-Hodjegan, Amin
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021, 2021, 61 : 225 - 245
  • [10] Comorbidity measures for use with administrative data
    Elixhauser, A
    Steiner, C
    Harris, DR
    Coffey, RN
    [J]. MEDICAL CARE, 1998, 36 (01) : 8 - 27